{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:36Z","timestamp":1783075956488,"version":"3.54.6"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,5,26]],"date-time":"2014-05-26T00:00:00Z","timestamp":1401062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec><jats:label\/><jats:p>Given the potential concomitant use of carbamazepine and paliperidone extended\u2010release (ER) in the treatment of schizophrenia or schizoaffective disorder, this open\u2010label, two\u2010treatment sequential study investigated the effect of repeated administration of carbamazepine on the steady\u2010state pharmacokinetics of paliperidone. Sixty\u2010four patients with a diagnosis of schizophrenia or bipolar\u2010I disorder received the following treatments in a fixed sequential order, without washout between treatments: (i) paliperidone ER 6\u2009mg tablet once daily for 7 days, and (ii) paliperidone ER 6\u2009mg once daily concomitantly with carbamazepine 200\u2009mg twice daily for the subsequent 21 days. Upon coadministration with carbamazepine, paliperidone steady\u2010state total exposure (AUC<jats:sub>24\u2009h<\/jats:sub>) and peak plasma concentrations (C<jats:sub>max<\/jats:sub>) decreased by approximately 37% [LSM ratio\u2014AUC<jats:sub>24\u2009h<\/jats:sub>: 63.4 (90% CI: 57.19; 70.29); C<jats:sub>max<\/jats:sub>: 62.47 (90% CI: 55.77; 69.98)]. This decrease is accounted for to a substantial degree by a 35% increase in renal clearance of paliperidone, likely as a result of induction of renal P\u2010glycoprotein by carbamazepine. A 14% decrease in the amount of drug excreted unchanged in the urine suggests that carbamazepine coadministration has a limited effect on the intestinal absorption or cytochrome metabolism of paliperidone.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cpdd.122","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T09:14:55Z","timestamp":1396084495000},"page":"371-377","source":"Crossref","is-referenced-by-count":17,"title":["Effect of carbamazepine on the pharmacokinetics of paliperidone extended\u2010release tablets at steady\u2010state"],"prefix":"10.1002","volume":"3","author":[{"given":"Virginie","family":"Kerbusch\u2010Herben","sequence":"first","affiliation":[{"name":"Janssen Research and Development Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Cleton","sequence":"additional","affiliation":[{"name":"Janssen Research and Development Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Berwaerts","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[{"name":"Janssen Research and Development Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[{"name":"Janssen Research and Development Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.02.011"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4137\/JCNSD.S1607"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02916252"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(96)01427-9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1989.tb01334.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/070674379604100513","article-title":"Adjunctive carbamazepine or lithium carbonate in therapy\u2010resistant chronic schizophrenia","volume":"41","author":"Simhandl C","year":"1996","journal-title":"Can J Psychiatry."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e318056f309"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02507.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050527"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00157.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1056-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018275"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00715-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.1004.1041"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1049"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05371.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPFAHVB26VVVTE"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0b013e3182966c2f","article-title":"Interaction between paliperidone and carbamazepine","volume":"35","author":"Yasui\u2010Furukori N","year":"2013","journal-title":"Ther Drug Monit."},{"key":"e_1_2_8_20_1","unstructured":"AnnaertP SteemansK MannensG.In vitro study on transepithelial transport of the psychotropic compound paliperidone (PAL) across Caco\u20102 monolayers.European ISSX Meeting at the Pharmaceutical Sciences Fair and Exhibition Nice France.2005."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.04.011"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443120-00001"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.27"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6663"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109797"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.11.009"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02587.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:05:30Z","timestamp":1696647930000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,26]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1002\/cpdd.122"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.122","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,26]]}}}